Drug Profile

ALLO 329

Alternative Names: ALLO-329

Latest Information Update: 23 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allogene Therapeutics
Class CAR-T cell therapies; Gene therapies; Immunotherapies; Skin disorder therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Myositis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

15 Apr 2026 Pharmacodynamics data from preclinical trials in Autoimmune diseases released by Allogene Therapeutics
13 Nov 2025 Phase-I clinical trials in Myositis (Treatment-resistant) in Canada (Parenteral) (NCT07085104)
13 Nov 2025 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-resistant) in Canada (Parenteral) (NCT07085104)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com